Furthermore, we showed that the synergistic anti-cancer effects by combining a novel SET antagonist, EMQA, and paclitaxel, and the synergism of this combination was determined by inhibition SET/PP2A/p-Akt signaling (Figures 5–7). This evidence concerns the gene AKT1 and cancer.